🎯
LATEST VERIFIED ALGORITHMIC EXECUTION
Quantitative engine captured a net profit of +19.26% on $OC in just 23h 32m.
CYT
$CYTK
🔒 US EquitiesCytokinetics, Incorporated
AVG HISTORICAL GAP
+0.18%
MAX GAP RECORD
+13.08%
🔒 PRO INSTITUTIONAL
AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡
SENTINEL HISTORICAL GAP VIEWER
// $CYTK
📊 1-YEAR TIMELINE (GAPS PLOTTED)
🔮 SIMULATE SETUP 🔒
GAP INSPECTION // PLAYBACK PROTOCOL
$CYTK
HISTORICAL GAP OCCURRENCE
Analyzing price jump between T-1 close and opening auction.
EVENT DATE—
GAP MAGNITUDE—
T-1 CLOSE—
OPEN PRICE—
AI DIRECTIONPRO ONLY 🔒
Bullish Opening Gap
Bearish Opening Gap
T-1 Close Baseline
CATALYSTS & GAP HISTORY
| Aug 06, 2026 Earnings Release 2026-08-06 (AFTER CLOSE) |
-0.17%
|
| May 05, 2026 Earnings Release 2026-05-05 (BEFORE OPEN) |
+13.08%
|
| Feb 24, 2026 Earnings Release 2026-02-24 (AFTER CLOSE) |
-2.82%
|
| Nov 05, 2025 Earnings Release 2025-11-05 (AFTER CLOSE) |
-0.57%
|
| Aug 07, 2025 Earnings Release 2025-08-07 (AFTER CLOSE) |
+1.70%
|
| May 06, 2025 Earnings Release 2025-05-06 (AFTER CLOSE) |
+4.03%
|
| Feb 27, 2025 Earnings Release 2025-02-27 (AFTER CLOSE) |
-6.51%
|
| Nov 06, 2024 Earnings Release 2024-11-06 (AFTER CLOSE) |
-0.92%
|
VOLATILITY & GAP BIAS
AVG GAP MOVE
3.2%
Bullish Gaps (5)
Bearish Gaps (5)
Neutral / Flat (5)
📖 Intelligence Summary
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten,…
NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗